Recursion Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

2 hours ago 3

Moby Intelligence

Wed, February 25, 2026 astatine 11:37 AM CST 3 min read

Management characterizes the existent signifier arsenic an 'inflection point' wherever the absorption shifts from gathering AI models to translating them into tangible objective grounds and measurable impact.
Performance is attributed to an 'end-to-end' integration of AI-driven biology, chemistry, and objective development, which absorption believes creates a compounding effect connected R&D decision-making.
The institution is utilizing a 'lab-in-the-loop' strategy to make high-quality, fit-for-purpose multimodal data, combining proprietary backstage information with nationalist datasets to guarantee unsocial exemplary insights.
Strategic positioning emphasizes 'repeatability' and 'scalability' successful cause discovery, aiming to alteration the traditionally probabilistic quality of biotech into a much predictable engineering-focused process.
Operational ratio is highlighted by the assertion of synthesizing 90% less compounds than the manufacture mean (300 vs. 2,500) and reaching improvement candidates doubly arsenic accelerated (17 months vs. 42 months).
Management attributes a 35% simplification successful operating expenses to a sharper portfolio focus, G&A optimization, and accrued level efficiency, alternatively than elemental cost-cutting.

The institution expects a engaged 18-24 period play with cardinal catalysts including FDA engagement for the REC-4881 (FAP) registration way successful 2026.
Guidance for 2026 currency operating expenses is acceptable nether $390 million, with a currency runway present extended into aboriginal 2028 based connected disciplined execution and probability-weighted concern milestones.
Go/no-go decisions for the PI3K and ENPP1 programs are expected successful the 2nd fractional of 2025 pursuing the completion of IND-enabling studies.
Future objective updates see aboriginal information and PK information for RBM39 successful precocious 2026, a akin update for MALT1 expected successful the archetypal fractional of 2027, and an update for LSD1 expected successful 2027.
The concern strategy assumes continued momentum with Sanofi and Roche Genentech, focusing connected translating biologic 'maps' into caller programs implicit the adjacent 18 months.

Management addressed NVIDIA's divestment, clarifying it was a portfolio displacement toward larger information halfway investments and does not interaction their ongoing method collaboration.
The institution transitioned to an 'outcomes-based budget' to guarantee each dollar spent is tied to a quantifiable strategical oregon technological outcome.
A 10% bushed connected erstwhile disbursal guidance was attributed to the palmy integration of firm systems and the completion of post-acquisition restructuring.
Management explicitly noted that cause find remains inherently probabilistic with a 90% manufacture nonaccomplishment rate, necessitating their 'multiple shots connected goal' level approach.